Kinneret Advisory LLC Buys New Position in Alexion Pharmaceuticals, Inc. (ALXN)
Kinneret Advisory LLC bought a new position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the fourth quarter, Holdings Channel reports. The fund bought 2,193 shares of the biopharmaceutical company’s stock, valued at approximately $214,000.
Several other hedge funds have also recently modified their holdings of the stock. Wedbush Securities Inc. boosted its stake in Alexion Pharmaceuticals by 1.5% in the fourth quarter. Wedbush Securities Inc. now owns 5,467 shares of the biopharmaceutical company’s stock valued at $532,000 after acquiring an additional 83 shares in the last quarter. Utah Retirement Systems boosted its stake in Alexion Pharmaceuticals by 0.3% in the fourth quarter. Utah Retirement Systems now owns 39,903 shares of the biopharmaceutical company’s stock valued at $3,885,000 after acquiring an additional 100 shares in the last quarter. Verity Asset Management Inc. boosted its stake in Alexion Pharmaceuticals by 4.4% in the fourth quarter. Verity Asset Management Inc. now owns 3,086 shares of the biopharmaceutical company’s stock valued at $300,000 after acquiring an additional 131 shares in the last quarter. Moody National Bank Trust Division boosted its stake in Alexion Pharmaceuticals by 0.6% in the fourth quarter. Moody National Bank Trust Division now owns 30,794 shares of the biopharmaceutical company’s stock valued at $2,998,000 after acquiring an additional 169 shares in the last quarter. Finally, Rafferty Asset Management LLC boosted its stake in Alexion Pharmaceuticals by 1.1% in the fourth quarter. Rafferty Asset Management LLC now owns 16,470 shares of the biopharmaceutical company’s stock valued at $1,604,000 after acquiring an additional 173 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.
Several equities analysts have issued reports on the stock. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday. Oppenheimer set a $165.00 target price on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Monday, November 26th. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, December 31st. Morgan Stanley upped their target price on shares of Alexion Pharmaceuticals from $165.00 to $175.00 and gave the company an “overweight” rating in a report on Tuesday, February 12th. Finally, Guggenheim started coverage on shares of Alexion Pharmaceuticals in a report on Friday, February 22nd. They issued a “neutral” rating and a $135.00 target price for the company. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $160.75.
Shares of NASDAQ:ALXN opened at $134.88 on Friday. Alexion Pharmaceuticals, Inc. has a one year low of $92.56 and a one year high of $140.77. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.88 and a quick ratio of 2.48. The stock has a market capitalization of $30.14 billion, a PE ratio of 19.02, a price-to-earnings-growth ratio of 1.00 and a beta of 1.55.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.54. The firm had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Alexion Pharmaceuticals had a net margin of 1.88% and a return on equity of 18.15%. The firm’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same period in the prior year, the company posted $1.48 earnings per share. As a group, sell-side analysts predict that Alexion Pharmaceuticals, Inc. will post 8.51 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Kinneret Advisory LLC Buys New Position in Alexion Pharmaceuticals, Inc. (ALXN)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2019/03/15/kinneret-advisory-llc-buys-new-position-in-alexion-pharmaceuticals-inc-alxn.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Read More: Insider Trading
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.